( NASDAQ-NMS:ARRY )

News from Array Biopharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 05, 2017, 08:00 ET Array BioPharma Submits New Drug Applications To FDA For Binimetinib And Encorafenib In Advanced Melanoma

Array BioPharma (Nasdaq: ARRY) today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to...


May 31, 2017, 03:00 ET Array BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib

Array BioPharma Inc. (Nasdaq: ARRY) and Ono Pharmaceutical Co., Ltd. ("Ono") today announced a license, development and commercialization...


May 30, 2017, 06:59 ET Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration

Array BioPharma (Nasdaq: ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research...


May 10, 2017, 08:00 ET Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017

- COLUMBUS / BRAF-mutant melanoma Part 2 demonstrates positive results and New Drug Application (NDA) filing on track for June or...


May 09, 2017, 16:01 ET Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma

Array BioPharma (Nasdaq: ARRY) today announced top-line results from Part 2 of the Phase 3 COLUMBUS study evaluating binimetinib, a MEK inhibitor,...


May 08, 2017, 08:00 ET Array BioPharma Announces Strategic Collaboration with Merck

Array BioPharma Inc. (Nasdaq: ARRY) announced today that it has entered into a clinical trial collaboration agreement with Merck (known as MSD...


May 03, 2017, 08:00 ET Array Biopharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017

Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2017 and hold a conference call to discuss those...


Feb 09, 2017, 08:30 ET Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2017

Array BioPharma Inc. (Nasdaq: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small...


Jan 03, 2017, 09:00 ET Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare...


Nov 22, 2016, 10:00 ET Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Piper Jaffray Annual...


Nov 09, 2016, 10:00 ET COLUMBUS Phase 3 Study Results in BRAF-Mutant Melanoma Presented at Society for Melanoma Research Annual Congress

Array BioPharma (Nasdaq: ARRY) and Pierre Fabre today jointly announced new results from the pivotal Phase 3 COLUMBUS trial of binimetinib plus...


Oct 03, 2016, 10:12 ET Array BioPharma Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

 Array BioPharma Inc. (NasdaqGM: ARRY) announced today the closing of its underwritten public offering of 21,160,000 shares of its common...


Sep 27, 2016, 16:27 ET Array BioPharma Announces Proposed Public Offering of Common Stock

 Array BioPharma (Nasdaq: ARRY) today announced that it has commenced an underwritten public offering of $100 million of shares of its common...


Sep 26, 2016, 07:00 ET Array BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint

Array BioPharma (Nasdaq: ARRY) and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used...


Sep 14, 2016, 07:30 ET Array BioPharma Announces Phase 3 BEACON CRC SPA Agreement with FDA

 Array BioPharma (Nasdaq: ARRY) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a...


Sep 06, 2016, 11:00 ET Array BioPharma To Present At The Morgan Stanley Global Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the 2016 Morgan Stanley Global...


Sep 01, 2016, 08:00 ET Array BioPharma Announces FDA Acceptance of Binimetinib NDA for Patients with Advanced NRAS-Mutant Melanoma

 Array BioPharma (Nasdaq: ARRY) today announced that the FDA has accepted its New Drug Application (NDA) for binimetinib with a target action...


Aug 30, 2016, 08:00 ET Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress

Array BioPharma (Nasdaq: ARRY) announced today results from a Phase 2 study of ARRY-797, an oral, selective p38 mitogen-activated protein kinase...


Aug 19, 2016, 15:26 ET Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress

 Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European...


Aug 09, 2016, 02:01 ET AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer

 AstraZeneca (LON/STO/NYSE: AZN) today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in...


Jun 30, 2016, 16:00 ET Array BioPharma Submits Binimetinib New Drug Application to U.S. FDA

 Array BioPharma (Nasdaq:  ARRY) today announced the submission of a New Drug Application (NDA) for binimetinib in patients with advanced...


Jun 06, 2016, 14:15 ET Array Presents Full Results from Phase 3 NEMO Study

 Array BioPharma (Nasdaq: ARRY) announced full results at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago...


Jun 04, 2016, 09:00 ET Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks

 Array BioPharma (Nasdaq: ARRY) announced today updated results from a Phase 2 study of the combination of encorafenib and cetuximab, with or...


Jun 04, 2016, 09:00 ET Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial

 Array BioPharma (Nasdaq: ARRY), Pierre Fabre and Merck KGaA, Darmstadt, Germany, today jointly initiated the BEACON CRC (Binimetinib,...


May 18, 2016, 17:05 ET Array BioPharma Announces Key Data from NRAS-mutant Melanoma and BRAF-mutant Colorectal Cancer ASCO 2016 Presentations

 Array BioPharma (NASDAQ: ARRY) will present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma...